US population for 2022 is 332.4 million with an ad
Post# of 153857
(Total Views: 1464)
Posted On: 05/03/2022 11:36:43 AM
US population for 2022 is 332.4 million with an adult population of 258.3 million. If 30-40% have NAFLD and 3-12% have NASH. Both someday possibly being treatable with a 14 week course of once a week Leronlimab. Or 14 injections at say $1,000 a dose or $14,000 for the 14 week treatment. Some will go longer if actually diagnosed with Nash. Nash patients might have to continue full time treatment until regression or until a liver is transplanted. Some patients may not to have another treatment after with a diet change to avoid and to not regress to NAFLD.
Having a treatment possibility of 30% of 258.3 million adults equals 77,490,000 potential NAFLD/NASH patients. Now what value is that for sales of Leronlimab?
77,490,000 adults with NAFLD at $14,000 per patient cost is $1,084,860,000,000. Or over a trillion dollars and not including full time treatment of the NASH patients who will stay on treatment for either longer or until transplant.
Of course this is the total population of just the USA and treating them would take years to catch up and help these people. When you consider the whole world population is in the same boat…Is there any wonder that every pharmaceutical company has trialed drugs and some multiple drug to treat NASH and NAFLD. The market is the largest treatable disease the world has ever seen. Nothing compares to this. Even Long Hauler’s treatment is no where close but clearly could become the worlds second largest treatment ever attempted when the right drug if found for both these diseases.
Does anyone know of a drug that could possibly treat both NAFLD/NASH and Long Hauler’s? If you do… you might want to pick up a few shares of stock in the company that might have this special drug. I am just say’n… hmmmm… quite the opportunity.
A week ago I doubled my holdings and that’s just me… had not bought any shares since 9/2019. Just seemed like an opportunity that dropped below my original purchase price average of .34/share. Now my average is .29/share and I am prepared to lose it all or travel the world on value realized from Leronlimab. Only time will tell.
Once again this just me and not investment advice. We all need to do our own research and the value of it. Good days ahead is all we hope for. A partnership for NAFLD/NASH could be the beginnings of something big. This is the hope we all have.
Having a treatment possibility of 30% of 258.3 million adults equals 77,490,000 potential NAFLD/NASH patients. Now what value is that for sales of Leronlimab?
77,490,000 adults with NAFLD at $14,000 per patient cost is $1,084,860,000,000. Or over a trillion dollars and not including full time treatment of the NASH patients who will stay on treatment for either longer or until transplant.
Of course this is the total population of just the USA and treating them would take years to catch up and help these people. When you consider the whole world population is in the same boat…Is there any wonder that every pharmaceutical company has trialed drugs and some multiple drug to treat NASH and NAFLD. The market is the largest treatable disease the world has ever seen. Nothing compares to this. Even Long Hauler’s treatment is no where close but clearly could become the worlds second largest treatment ever attempted when the right drug if found for both these diseases.
Does anyone know of a drug that could possibly treat both NAFLD/NASH and Long Hauler’s? If you do… you might want to pick up a few shares of stock in the company that might have this special drug. I am just say’n… hmmmm… quite the opportunity.
A week ago I doubled my holdings and that’s just me… had not bought any shares since 9/2019. Just seemed like an opportunity that dropped below my original purchase price average of .34/share. Now my average is .29/share and I am prepared to lose it all or travel the world on value realized from Leronlimab. Only time will tell.
Once again this just me and not investment advice. We all need to do our own research and the value of it. Good days ahead is all we hope for. A partnership for NAFLD/NASH could be the beginnings of something big. This is the hope we all have.
(7)
(0)